JAMA

Risk of Stomach and Digestive Problems Linked to Weight-Loss Drugs Acting on GLP-1 Receptors

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Conflict of Interest Disclosures: None reported.
PubMed

Related papers

Aug '16
How drugs that activate GLP-1 receptors help manage obesity
top 50% journal
cited by 60 papers
journal article
May '22
Weight loss effects and safety of GLP-1 receptor drugs in overweight or obese people without diabetes
cited by 51 papers
systematic review
Jan '12
Weight loss linked to drugs that activate the glucagon-like peptide-1 receptor: a review of clinical trials
top 5% journal
cited by 798 papers
systematic review
Jan '17
Stomach and intestinal side effects of glucagon-like peptide-1 receptor drugs: how often they occur and their impact
cited by 64 papers
randomized controlled trial

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief